Internal Medicine,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Jan. 1, 2024
A
79-year-old
man
with
smoldering
multiple
myeloma
(MM)
developed
sudden
severe
thrombocytopenia
and
active
bleeding.
Since
anti-GPIIb/IIIa
autoantibodies
were
detected
on
the
platelet
surface,
due
to
an
autoimmune
etiology
was
diagnosed.
Although
neither
steroids
nor
intravenous
immunoglobulins
provided
improvement,
bortezomib
rapid
normalization
of
counts
disappearance
anti-GPIIb/IIIb
autoantibodies.
MM
is
rarely
associated
immune
thrombocytopenic
purpura
(ITP).
underlying
pathogenesis
ITP
remains
elusive,
anti-myeloma
drugs
might
be
beneficial.
New England Journal of Medicine,
Journal Year:
2024,
Volume and Issue:
391(2), P. 122 - 132
Published: May 25, 2024
Antibody-mediated
rejection
is
a
leading
cause
of
kidney-transplant
failure.
The
targeting
CD38
to
inhibit
graft
injury
caused
by
alloantibodies
and
natural
killer
(NK)
cells
may
be
therapeutic
option.
Lupus Science & Medicine,
Journal Year:
2024,
Volume and Issue:
11(1), P. e001112 - e001112
Published: March 1, 2024
To
evaluate
safety
and
mechanism
of
action
mezagitamab
(TAK-079),
an
anti-CD38
monoclonal
antibody,
in
patients
with
moderate
to
severe
systemic
lupus
erythematosus
(SLE).
Lara D. Veeken,
Journal Year:
2024,
Volume and Issue:
63(11), P. 2938 - 2947
Published: Feb. 6, 2024
Idiopathic
inflammatory
myopathies
(IIMs)
are
a
rare
and
heterogeneous
group
of
chronic
autoimmune
disorders.
Up
to
40%
IIM
patients
have
long-term
sequelae
significant
functional
disability.
Its
management
can
be
challenging
new
therapies
badly
needed.
The
small
number
cases
with
diverse
presentations
different
diagnostic
criteria
significantly
affect
clinical
trial
results.
Only
IVIG
has
been
internationally
approved
for
patients.
Most
trials
biologic
failed
meet
their
primary
endpoints
in
IIM,
only
one
drug
recommended
refractory
treatment
(rituximab),
although
not
approved.
We
review
several
emerging
drugs,
including
B
cell
depletion
therapies,
abatacept,
Janus
kinase
inhibitors,
aldesleukin.
Encouragingly,
some
phase
II
randomized
controlled
evaluated
the
efficacy
safety
biologics
demonstrating
an
improvement
laboratory
measures.
Expert Opinion on Investigational Drugs,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 10, 2025
Introduction
Felzartamab
is
a
novel,
fully
human
CD38
monoclonal
antibody,
currently
in
development
for
the
treatment
of
antibody-mediated
rejection
(AMR)
following
kidney
transplantation.
Therapeutic Advances in Neurological Disorders,
Journal Year:
2025,
Volume and Issue:
18
Published: Jan. 1, 2025
Neuromyelitis
optic
spectrum
disorder
(NMOSD)
is
a
rare
autoimmune
disease
characterized
by
recurrent
episodes
and
severe
debilitation.
It
primarily
involves
the
central
nervous
system
associated
with
presence
of
aquaporin-4
antibodies.
Effective
management
NMOSD
necessitates
long-term
therapeutic
strategies
that
focus
on
alleviating
symptoms
during
acute
preventing
relapse.
In
recent
years,
approval
emerging
biologics
targeting
B
cells,
interleukin-6
receptors,
complement
pathway
has
marked
transformative
development
in
treatment.
This
article
provides
comprehensive
review
advances
NMOSD,
integrating
current
literature
to
serve
as
theoretical
basis
for
clinical
decision-making
patients.
Critical Care,
Journal Year:
2025,
Volume and Issue:
29(1)
Published: April 17, 2025
Abstract
Background
Vacuoles,
E1
enzyme,
X-linked,
autoinflammatory,
somatic
(VEXAS)
syndrome
is
a
recently
discovered
severe
disorder
that
predominantly
affects
adult
males,
characterized
by
systemic
inflammation
and
hematologic
abnormalities.
Despite
its
profound
impact
on
patient
outcomes,
awareness
of
VEXAS
among
critical
care
providers
remains
severely
limited,
often
leading
to
delayed
recognition,
diagnosis,
initiation
appropriate
treatment.
This
study
aims
address
this
knowledge
gap
conducting
scoping
review
in
the
setting.
Methods
followed
PRISMA-ScR
guidelines
Joanna
Briggs
Institute
methodology,
analyzing
data
from
Cochrane
CENTRAL,
MEDLINE
via
PubMed,
EMBASE,
Web
Science
May
19,
2024.
We
included
studies
reported
clinical
features
treatments
patients
with
requiring
care.
Results
Of
1262
reports
identified,
78
met
inclusion
criteria,
including
45
case
reports/series,
17
observational
studies,
15
reviews,
one
systematic
review.
Analysis
55
cases
revealed
median
age
69
strong
male
predominance
(54/55).
ICU
admission
rates
ranged
28
33%,
mortality
between
18
40%.
Critical
manifestations
shock,
hemophagocytic
lymphohistiocytosis,
acute
respiratory
distress
syndrome,
thrombosis,
airway
edema.
Sepsis
was
cause
death,
other
causes
related
organ
failure,
cardiovascular
events,
intestinal
perforation.
Treatment
approaches
combined
conventional
measures
immunosuppressive
immunomodulatory
therapies,
although
infectious
complications
were
frequently
reported.
Conclusion
lack
systematically
analyzed
focusing
setting,
suggesting
significant
understanding
characteristics
optimal
for
syndrome.
Further
research
focused
setting
essential
improve
early
develop
standardized
treatment
protocols,
ultimately
outcomes
complex
population.
Cell Death Discovery,
Journal Year:
2025,
Volume and Issue:
11(1)
Published: April 29, 2025
Autoimmune
encephalitis
(AE)
is
increasingly
recognized
as
a
cause
of
brain
disorders
that
greatly
benefit
from
immunotherapy.
Starting
treatment
quickly
and
increasing
the
use
immunotherapy
can
lead
to
better
results
for
AE
patients.
Currently,
there
are
standardized
guidelines
treating
AE.
First-line
therapy
includes
intravenous
corticosteroids,
plasma
exchange,
immunoglobulin.
Second-line
involves
rituximab,
cyclophosphamide,
mycophenolate
mofetil,
azathioprine.
Third-line
uses
agents
deplete
cells
(bortezomib,
daratumumab,
obinutuzumab),
drugs
modulate
cytokines
(tocilizumab,
anakinra,
tofacitinib,
interleukin-2),
treatments
target
intrathecal
immune
(intrathecal
methotrexate).
This
review
aims
summarize
immunotherapeutic
strategies
available
provide
an
update
on
refractory
